The Chosun Ilbo on MSN
MSD's Keytruda subcutaneous form approved, marking 1-minute anticancer drug era
A subcutaneous (SC) form of immune anticancer drug that can be administered in 1 to 2 minutes by injection into the skin has ...
Biotech corporations Ingenia Therapeutics cleared the preliminary review for a KOSDAQ listing, kicking off its initial public offering process. The ophthalmic disease therapy the company is ...
GlobalData on MSN
MSD and Adcendo sign collaboration agreement for Phase Ib trial
Adcendo will sponsor the Phase Ib clinical trial, and MSD will provide pembrolizumab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results